Chia-Jui Yen

5.5k total citations · 1 hit paper
63 papers, 2.7k citations indexed

About

Chia-Jui Yen is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Chia-Jui Yen has authored 63 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 26 papers in Oncology and 12 papers in Hepatology. Recurrent topics in Chia-Jui Yen's work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Liver physiology and pathology (6 papers) and MicroRNA in disease regulation (5 papers). Chia-Jui Yen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Liver physiology and pathology (6 papers) and MicroRNA in disease regulation (5 papers). Chia-Jui Yen collaborates with scholars based in Taiwan, United States and South Korea. Chia-Jui Yen's co-authors include Masatoshi Kudo, Baek‐Yeol Ryoo, Hyun Cheol Chung, Paolo Abada, Andrew X. Zhu, Joon Oh Park, Takuji Okusaka, Ian Chau, Davide Pastorelli and Ling Yang and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Chia-Jui Yen

63 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Chia-Jui Yen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chia-Jui Yen Taiwan	28	1.1k	955	777	613	530	63	2.7k
Jianhua Wang China	27	772 0.7×	615 0.6×	592 0.8×	542 0.9×	522 1.0×	111	2.5k
Wang Li China	27	769 0.7×	543 0.6×	376 0.5×	470 0.8×	497 0.9×	108	2.0k
Jeremias Wohlschlaeger Germany	30	1.1k 1.0×	646 0.7×	350 0.5×	459 0.7×	579 1.1×	114	2.8k
Zhan‐Hong Chen China	22	1.0k 1.0×	555 0.6×	227 0.3×	838 1.4×	261 0.5×	65	1.9k
Hirofumi Akita Japan	28	1.1k 1.0×	1.5k 1.6×	632 0.8×	813 1.3×	710 1.3×	184	3.2k
Xiaobo Yang China	30	1.0k 1.0×	1.0k 1.1×	396 0.5×	999 1.6×	727 1.4×	100	2.6k
Akira Mitoro Japan	24	703 0.7×	352 0.4×	392 0.5×	360 0.6×	274 0.5×	103	1.9k
Cindy Neuzillet France	29	1.2k 1.2×	2.2k 2.3×	177 0.2×	736 1.2×	657 1.2×	136	3.5k
Suimin Qiu United States	26	1.0k 1.0×	942 1.0×	110 0.1×	428 0.7×	234 0.4×	91	2.5k
Oronzo Brunetti Italy	35	1.1k 1.0×	1.5k 1.6×	280 0.4×	783 1.3×	525 1.0×	126	3.1k

Countries citing papers authored by Chia-Jui Yen

Since Specialization

Citations

This map shows the geographic impact of Chia-Jui Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia-Jui Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia-Jui Yen more than expected).

Fields of papers citing papers by Chia-Jui Yen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chia-Jui Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia-Jui Yen. The network helps show where Chia-Jui Yen may publish in the future.

Co-authorship network of co-authors of Chia-Jui Yen

This figure shows the co-authorship network connecting the top 25 collaborators of Chia-Jui Yen. A scholar is included among the top collaborators of Chia-Jui Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chia-Jui Yen. Chia-Jui Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adkins, Douglas R., Assuntina G. Sacco, Jessica Ley, et al.. (2021). Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Oral Oncology. 115. 105192–105192. 27 indexed citations

Su, Yung‐Yeh, Nai‐Jung Chiang, Hui‐Jen Tsai, et al.. (2020). The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Scientific Reports. 10(1). 7420–7420. 22 indexed citations

Yen, Chia-Jui, et al.. (2018). NEK2 Promotes Hepatoma Metastasis and Serves as Biomarker for High Recurrence Risk after Hepatic Resection. Annals of Hepatology. 17(5). 843–856. 15 indexed citations

Yen, Chia-Jui, B. Markman, Yee Chao, et al.. (2017). Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. iii54–iii54. 11 indexed citations

Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413. 58 indexed citations

Wang, Wei‐Jan, Chien‐Feng Li, Yu‐Yi Chu, et al.. (2016). Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. Clinical Cancer Research. 23(2). 503–513. 51 indexed citations

Chang, Hong, Chung-Ta Lee, Chia-Jui Yen, et al.. (2016). RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break–Inducing Anticancer Drugs. Molecular Cancer Therapeutics. 15(2). 276–286. 14 indexed citations

Chan, Tze‐Sian, Chung‐Chi Hsu, Wen‐Ying Liao, et al.. (2016). Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. The Journal of Experimental Medicine. 213(13). 2967–2988. 132 indexed citations

Yen, Chia-Jui, et al.. (2016). Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget. 8(4). 6406–6418. 49 indexed citations

10.

Li, Chien‐Feng, et al.. (2015). HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells. Molecular Cancer Therapeutics. 14(11). 2623–2633. 17 indexed citations

11.

Chen, Yun‐Ju, et al.. (2015). HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 7(1). 473–489. 20 indexed citations

12.

Yen, Chia-Jui, et al.. (2015). The B56γ3 regulatory subunit-containing protein phosphatase 2A outcompetes Akt to regulate p27KIP1 subcellular localization by selectively dephosphorylating phospho-Thr157 of p27KIP1. Oncotarget. 7(4). 4542–4558. 9 indexed citations

13.

Shen, Ying‐Chun, Chung‐Pin Li, Chia-Jui Yen, et al.. (2014). Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology. 87(2). 104–113. 15 indexed citations

14.

Wu, Shang‐Yin, Yuan-Hua Wu, Wei‐Ting Hsueh, et al.. (2014). Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. BMC Cancer. 14(1). 787–787. 18 indexed citations

15.

Hsia, Te‐Chun, Chih‐Yen Tu, Yun‐Ju Chen, et al.. (2013). Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells. Molecular Pharmacology. 83(4). 857–869. 34 indexed citations

16.

Tsai, Hung-Wen, Yu-Chung Chang, Chia-Jui Yen, et al.. (2013). Lin28B Is an Oncofetal Circulating Cancer Stem Cell-Like Marker Associated with Recurrence of Hepatocellular Carcinoma. PLoS ONE. 8(11). e80053–e80053. 48 indexed citations

17.

Chang, Kwang‐Yu, et al.. (2011). Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo. Clinical Cancer Research. 17(22). 7116–7126. 97 indexed citations

18.

Chen, Chun‐Te, Hirohito Yamaguchi, Hong-Jen Lee, et al.. (2011). Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase. Molecular Cancer Therapeutics. 10(8). 1327–1336. 21 indexed citations

19.

Yen, Chia-Jui, Julie Izzo, Dung‐Fang Lee, et al.. (2008). Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma. Cancer Research. 68(8). 2632–2640. 49 indexed citations

20.

Ding, Qingqing, Longfei Huo, Jer-Yen Yang, et al.. (2008). Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. Cancer Research. 68(15). 6109–6117. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact